{
    "id": 4353,
    "fullName": "KDR R1032Q",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KDR (VEGFR2) R1032Q lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1032Q results in decreased ligand-induced phosphorylation of Kdr (Vegfr2) and Mapk in cell culture (PMID: 28743916), but induces tumor growth in mouse models above wild-type protein (PMID: 29588308), and therefore, its effect on Kdr (Vegfr2) protein function is unknown.",
            "references": [
                {
                    "id": 10127,
                    "pubMedId": 28743916,
                    "title": "Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28743916"
                },
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3791,
        "geneSymbol": "KDR",
        "terms": [
            "KDR",
            "CD309",
            "FLK1",
            "VEGFR",
            "VEGFR2"
        ]
    },
    "variant": "R1032Q",
    "createDate": "04/01/2015",
    "updateDate": "02/03/2020",
    "referenceTranscriptCoordinates": {
        "id": 102209,
        "transcript": "NM_002253",
        "gDna": "chr4:g.55090053C>T",
        "cDna": "c.3095G>A",
        "protein": "p.R1032Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15428,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited reduced ERK phosphorylation and inhibited growth of a colorectal cancer cell line harboring KDR (VEGFR2) R1032Q in culture (PMID: 29588308).",
            "molecularProfile": {
                "id": 4159,
                "profileName": "KDR R1032Q"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of KDR (VEGFR2) R1032Q in a colorectal cancer cell line resulted in increased sensitivity to Lenvima (lenvatinib), leading to increased growth inhibition in culture (PMID: 29588308).",
            "molecularProfile": {
                "id": 4159,
                "profileName": "KDR R1032Q"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12199,
                    "pubMedId": 29588308,
                    "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29588308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4159,
            "profileName": "KDR R1032Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102209,
            "transcript": "NM_002253",
            "gDna": "chr4:g.55090053C>T",
            "cDna": "c.3095G>A",
            "protein": "p.R1032Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}